Riastap Advisory Committee Review Will Evaluate Surrogate Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
CSL Behring seeks accelerated approval for the first human fibrinogen concentrate since the products were withdrawn in 1977, but FDA first wants validation of the surrogate endpoint used to show efficacy.